drugset / Trial / NCT02203422
A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）
RandomizedParallel-groupDouble-blindTreatment
Summary
The project was undertaking by Qilu Hospital of Shandong University and other 5 well-known hospitals in China. In order to report the efficacy and safety of recombinant human thrombopoietin combining with cyclosporin A for the treatment of adults with refractory immune thrombocytopenia (ITP), compared to cyclosporin A monotherapy.
Timeline
- Start
- 2014-07
- Primary completion
- 2015-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | 1.5 mg/kg | Oral |
| Subject | Cyclosporine | Peptide | 2 mg/kg | Oral |
| Subject | recombinant human thrombopoietin | Protein / enzyme biologic | 300 iu/kg | Subcutaneous |